PROSTATE CANCER is the most common cancer and the second leading cause of cancer death affecting men in the United States. As life expectancy increases, so will the incidence of this disease, creating what will become a major public health problem. Prostate cancer is clinically a heterogeneous disease characterized by biologic behavior that ranges between indolent and aggressive states. The exact molecular basis for the observed disease heterogeneity is not well understood.
metabolism of androgen, androgen receptor (AR) and coregulators, AR-regulated genes (eg, gonadotropinreleasing hormone [Gn-RH] receptors), and deletions or loss of expression of tumor suppressor genes (p27, p53, PTEN, GSTP1). For example, PTEN inactivation (phosphatase and tensin homologue deleted on chromosome 10), which has been noted to be associated with high-grade prostate tumors and with tumor progression, may exert its effect through upregulation of cell cycle genes such as cdc6 and cyclin E2, which, in turn, potentiate metastatic disease. 15 Other genetic and molecular abnormalities may include CYP17 (encoding cytochrome P-450c17α, which is responsible for testosterone synthesis), SRD5A2 (encoding 5α-reductase isoenzyme, which converts testosterone to the more potent dihydrotestosterone), HPC1/RANSEL (a ribonuclease that degrades ribonucleic acid [RNA] ), c-Kit/tyrosine kinase receptor (activator of the Src family of tyrosine kinases), hespin (a type II transmembrane serine protease), EPCA (early prostate cancer antigen that is a nuclear matrix protein), and vitamin D receptor. 2 Recently, it has been observed that induction and upregulation of stress response protein GRP78 (78 kDa glucose regulated protein) are associated with the development and survival of castrationresistant prostate cancer cells in an androgen-deficient microenvironment. 16, 17 Serum prostate-specific antigen (PSA) has long been used as an organ-specific marker and is currently the most commonly used marker for prostate cancer. PSA is a 33 kDa androgen-regulated serine protease that is produced by the prostate gland. Age-specific normal ranges have been determined because the standard PSA reference range of 0.0 to 0.4 ng/mL does not account for age and volume changes in relation to benign prostatic hyperplasia (BPH). 2 However, PSA and other related parameters (eg, PSA density, PSA velocity, free and complexed PSA) have limited sensitivity (may be undetectable or low even in disseminated disease) and limited specificity (a high level with benign disease) for prostate cancer, cannot localize the disease if present, may be affected in a manner unrelated to the impact of therapy on tumor, and are the cause of great anxiety and overstated diagnostic expectations by the patient, coined "PSA-itis." [18] [19] [20] Another relevant prostate biomarker is the prostatespecific membrane antigen (PSMA), which is a glycoprotein expressed in both the benign and the neoplastic prostatic epithelial cells and in other tissues, such as kidney, liver, and brain. 21, 22 It is upregulated in hormone-resistant states and in metastatic disease. 22, 23 Androgens are also essential for the development, growth, and maintenance of the prostate. The effects of androgens are exerted via the nuclear AR, which is a ligand-dependent (either testosterone or 5α-dihydrotestosterone) transcription activator involved in cellular proliferation and differentiation and is present in all histologic types of prostate tumors, in recurrent carcinoma, and in tumor metastases. 24, 25 Most patients respond favorably to androgen ablation, but nearly all patients will relapse to the castrationresistant clinical state that may be due to AR mutation or aberrant function (eg, receptor activation in a ligandindependent manner), amplification of coactivators, activation of oncogenes, and autocrine growth factor stimulation.
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Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy
Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) have been employed in the detection and characterization of prostate cancer. [27] [28] [29] Dynamic contrast-enhanced MRI with smallmolecular-weight gadolinium chelates and highermolecular-weight P792 have been studied. 30, 31 Despite the observation of a slower washout rate of the contrast agent from metastatic tumors than nonmetastatic tumors, generally significant limitations and overlap have been noted in relation to differential characterization with benign conditions such as prostatitis and BPH. 32 Recent reports of using lymphotropic superparamagnetic nanoparticles in conjunction with highresolution MRI may allow the detection of small and otherwise undetectable lymph node metastases in patients with prostate cancer. 33 However, the exact clinical utility of such a diagnostic imaging approach remains to be determined.
In one study, prostate cancer cells were directly imaged using an intracellular MRI contrast agent that was designed by using the c-myc messenger ribonucleic acid (mRNA)-specific peptide nucleic acid as a "retention" contrast agent. 34 Researchers at Harvard Medical School studied the gene expression profile underlying the magnetic resonance-derived imaging and MRS-derived spectral features of prostate cancer. 35 The RNA expression profiles were obtained from the Affymetrix Gene Chip microarrays and quantitative reverse transcriptase polymerase chain reaction analysis. An overexpression of choline kinase was noted in the majority of primary tumors and neuropeptide Y (an angiogenic factor) in a subset of prostate tumors visualized on dynamic contrastenhanced MRI. In another related study for assessing gene expression in vivo, the proof of principle work for using [
19 F] MRS for assessing β-galactosidase activity was reported demonstrating the ability to differentiate wild-type from lacZ gene (encoding β-galactosidase) expressing androgen-independent PC3 prostate tumor xenografts in mice. 36 These studies illustrate the correlation of MRI and MRS parameters to the underlying molecular events in prostate cancer.
In another work, biotinylated anti-PSMA antibody was conjugated to streptavidin-labeled iron oxide nanoparticles for MRI detection of prostate cancer cells.
37 T 1 -weighted signal was greater for cells with magnetic particles bound to cell surface than for cells that internalized the particles, whereas no such effect was noted with T 2 -weighted images. MRIderived functional diffusion maps have also been found to be useful in assessing treatment response in a preclinical model of prostate cancer bone metastasis. 38 The functional diffusion map demonstrated an increase in water diffusion in relation to loss of tumor cell membrane integrity and density induced by successful therapy. Further clinical evaluation of this concept in comparison with standard imaging studies such as bone scintigraphy may provide a more sensitive imaging-based marker for early assessment of treatment response.
Single-Photon Emission Tomography and Positron Emission Tomography
Despite the relevance of PSMA in prostate cancer, Prostascint (Cytogen, Princeton, NJ), a radiolabeled antibody targeted to the PSMA, has been found to have several significant shortcomings, including limited predictive value in imaging the prostate fossa, particularly following radiation therapy, and low sensitivity for detecting osseous metastases; Prostascint is also technically demanding and requires interpretation at sites with experience and expertise. 39 Recently, investigators from Johns Hopkins University presented the preparation of radiolabeled small-molecule ligands for [40] [41] [42] These efforts were based on potential capitalization on PSMA as a relevant biologic target for imaging and therapy of prostate cancer.
Positron emission tomography (PET) with [ 18 F]-fluorodeoxyglucose (FDG) is a molecular imaging technique that monitors tissue glucose metabolism, taking advantage of the long-known phenomenon that most tumors are hypermetabolic with increased glucose metabolism (Warburg effect). The upregulation of glucose transporter (GLUT) proteins (primarily GLUT1 and/or GLUT3) and/or increased hexokinase (HK) enzymatic level and activity (primarily HK-II) have been observed in many cancers. [43] [44] [45] GLUT is the first rate-limiting step for glucose metabolism that allows energy-independent glucose transport across the cell membrane down the concentration gradient, whereas HK-II efficiently phosphorylates glucose to glucose-6-phosphate. Similar to glucose, FDG is phosphorylated to FDG-6-phosphate, but contrary to glucose-6-phosphate, it cannot be metabolized further in the glycolytic pathway and becomes trapped in the cell owing to its negative charge. [43] [44] [45] Few studies have reported specifically on expression of GLUTs in human prostate cancer. In one investigation, the GLUT1 mRNA expression was assessed by Northern blot analysis in the androgen-independent cell lines DU145 and PC3 and the androgen-sensitive LNCaP prostate cancer cell line. 46 Although GLUT1 expression was detected in all three cell lines, the level of expression was higher in the poorly differentiated cell lines DU145 and PC3 than in the well-differentiated hormone-sensitive LNCaP cell line, suggesting that the level of GLUT1 expression increases with progression of malignancy grade. Another study from Australia showed the expression of GLUT12 in human prostate cancer cell lines with its potential implication on enhanced glucose metabolism in prostate tumor. 47 Recently, British investigators evaluated the expression of a number of hypoxia-associated genes within BPH and prostate cancer (Gleason score 5-10) human tissue specimens.
48 GLUT1 gene expression was significantly higher in prostate cancer than in BPH and was correlated directly with Gleason score (R = .274, p = .026). These findings may explain not only the observation of higher FDG accumulation in the castra-tion-resistant (androgen-independent) tumors in comparison with castration-sensitive tumors but also the modulatory effect of androgen on the glucose metabolism of the castration-sensitive tumors. 49 Two non-FDG PET tracers ( 11 C-or 18 F-labeled acetate and choline) have been relatively extensively studied in prostate cancer. [50] [51] [52] The cellular retention of 11 C acetate in prostate cancer cell lines is primarily due to incorporation of the radiocarbon into phosphatidylcholine and neutral lipids of the cells. 53, 54 It has been suggested that fatty acid metabolism rather than glycolysis may be dominant in prostate cancer in view of alteration in several enzymes involved in the metabolism of fatty acids and enhanced beta-oxidation pathway. 55 Recent studies confirmed the involvement of the fatty acid synthesis pathway in 11 C acetate uptake in prostate tumors as an imaging marker for fatty acid synthase expression. 56 Fatty acid synthase is the major enzyme required for converting carbohydrates to fatty acids, and its upregulation plays a role in tumorigenesis of the prostate in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. 57 The biologic basis for radiolabeled choline uptake in tumors is the malignancy-induced upregulation of choline kinase, which leads to the incorporation and trapping of choline in the form of phosphatidylcholine (lecithin) in the tumor cell membrane. 58 Choline uptake in prostate tumor appears to be uncorrelated to cellular proliferation (as depicted by Ki-67) but may be affected by hypoxia. 59, 60 It has also been demonstrated that under aerobic conditions, both androgen-sensitive and androgen-independent prostate tumors show higher choline uptake than that with radiolabeled acetate or with FDG. However, during hypoxia, the tumor uptake with FDG and acetate is higher than that with choline. 59 Furthermore, recent work has suggested that the uptake time interval and castration do not appear to significantly affect the level of radiolabeled choline uptake by the human prostate cancer xenograft. 61 Recently, [ 11 C]acetoacetate has also been evaluated as a potential PET tracer of ketone body use by prostate tumors. 62 It was shown that PC-3 androgenindependent prostate tumors display moderate uptake of [
11 C]acetoacetate with rapidly decreasing background activity. Further research would be needed to determine the exact biologic relevance of imaging ketone body use to the natural history of prostate cancer and how it may be useful in a specific clinical setting.
With respect to the AR imaging, PET tracers such as 16β- 18 F-fluoro-5α-dihydrotestosterone ( 18 F-FDHT) targeted to the AR have been developed and evaluated. 63, 64 Metabolism of 18 F-FDHT was rapid, with 80% conversion within 10 minutes to radiolabeled metabolites bound to plasma proteins. The tracer uptake level in prostate tumors was also demonstrated to decrease significantly in response to androgen ablation therapy, supporting the receptor-mediated process of 18 F-FDHT uptake. 65 It has also been shown that pharmacologic AR inhibition (eg, flutamide) and androgen withdrawal exert their therapeutic effects in androgendependent tumors through different molecular mechanisms. 66 Interestingly, the antiandrogenic effect of treatment appears to decrease glucose metabolism in prostate cancer, which then can be monitored with FDG or used to potentially predict the development of castration-resistant disease. 49 Other androgen-related agents have also been synthesized to explore the effect of the sex hormone-binding globulin in the target tissue uptake of AR radiotracers. 67, 68 It has been noted that some tumors, including prostate cancer (mostly androgen-independent), overexpress gastrin-releasing peptide (GRP) receptors. Radiolabeled bombesin (a neuropeptide with high affinity for GRP receptors) analogues have been synthesized and evaluated for single-photon emission computed tomography (SPECT) ( 111 In label) and PET ( 64 Cu or 18 F label) visualization of prostate cancer. [69] [70] [71] Whether imaging the GRP receptor is deemed clinically useful will need further investigation in relation to various stages and markers of the disease.
In relation to tumor angiogenesis, the vascular endothelial growth factor signaling pathway and the integrin α v β 3 (a cell adhesion molecule) have been identified to play key roles. Molecular imaging of these targets in the tumor vasculature may help tailor targeted antiangiogenic therapy. 72, 73 A number of PET tracers suitable for integrin receptor imaging have been reported that demonstrate high specificity in various types of tumors, including prostate cancer models. 74 However, active research continues in identifying more specific biologic markers for interrogating the tumor vessels. These investigations will not only shed more light on the biologic basis of the complex signals involved in malignancy-induced angiogenesis but may also help facilitate the design and image-based testing of drugs targeted to tumorspecific angiogenesis.
Singh and colleagues recently reviewed various strategies for molecular imaging of reporter gene expression in prostate cancer. 75 These methods involve the introduction of a reporter gene into the target cell via a particular vehicle (viral or nonviral) with the gene expressed by a particular promoter. The promoter may be tissue specific, inducible, or constitutive. The ultimate reporter protein product (eg, enzyme, receptor) then interacts with the appropriate reporter probe, producing an imaging signal that becomes available for detection. When the reporter gene is combined with a therapeutic (suicide) gene, tissue-specific (prostate tumor) expression of the therapeutic gene may be inferred through the expression of the reporter gene as interrogated by the reporter probe. 76 The overall goal of these strategies is to monitor in vivo the successful delivery and spatiotemporal expression of the therapeutic gene. An example of such a strategy is the PET imaging of the adenovirus-delivered herpes simplex virus thymidine kinase (HSV-tk) reporter gene in conjunction with the 18 F-FHBG reporter probe. 77 Recent work has shown improved target specificity for delivery and expression of the therapeutic gene in prostate cancer bone metastases. 78 In this study, dualtargeted lentiviral vectors were developed that interact with prostate stem cell antigen expressed on prostate cancer cells with transcriptional specificity mediated by a prostate cell-specific promoter. Strategies such as two-step transcriptional amplification-based lentiviral vector have also been reported to facilitate appropriate in vivo targeting of prostate cancer after systemic administration of the vector that is considered a valuable component in the eventual adoption of gene therapy protocols. [79] [80] [81] [82] Another mechanism involves exogenous transfection of prostate cancer cells with the Na/I symporter (a plasma membrane glycoprotein involved in active thyroid iodine uptake) that allows tumor killing through radioiodine therapy. 83 Sentinel lymph node (SLN) technique for staging has been used for many cancers, in particular melanoma and breast cancer. Investigators from UCLA extended this general technique for directly imaging SLN metastasis in prostate cancer. 84 In this work, the lymphotropic recombinant human adenoviral vectors were used containing prostate-restricted expression of optical and PET reporter genes. The peritumoral administration of the vector allowed direct visualization of reporter gene expression in SLN metastases. Bone is also a common site of metastatic disease in prostate cancer. Whole-body 18 F-fluoride ion micro-PET has been used to serially monitor the tumor development and response to treatment in mouse models of prostate cancer osseous metastatic disease, and when combined with micro-CT, correlative structural changes could also be interrogated. 85 
Optical Imaging
Engineered mouse models of prostate cancer have been developed in conjunction with imaging markers to allow in vivo monitoring of tumor growth at different stages of the disease and to facilitate the translation of the mouse studies into human clinical trials. [86] [87] [88] [89] [90] In one model, for example, the feasibility of generating bigenic mice by crossbreeding the sPSA-Luc transgenic mouse model (with luciferase gene expression restricted to the prostate under control of the supra PSA promoter) with the TRAMP model. 87 These animal models may provide the platform for in vivo imaging of prostate cancer progression from a localized process to the disseminated state.
It has been noted that increased expression of a splice variant of the Kruppel-like factor tumor suppressor gene (KLF6-SV1) in the excised prostate tumor predicts poor prognosis and earlier time to recurrence. This gene is also upregulated in hormonerefractory metastatic prostate cancer. Bioluminescent imaging (BLI) in mouse models of prostate cancer has been used to demonstrate that KLF6-SV1 overexpression is associated with increased propensity for metastatic spread to lymph nodes, whereas there is little effect on localized tumor growth. 91 Similarly, exogenous hepsin expression also negatively regulates cell growth in metastatic prostate cancer cell lines, which may link the decrease in or loss of hepsin expression to poor prognosis. 92 Imaging probes for hepsin have been developed by conjugating multiple peptides to fluorescent nanoparticles that bind specifically to hespin-expressing prostate cancer xenografts. 93 In another investigation, in vivo quantitative BLI was used to document the liposomeencapsulated human alphav-siRNA (small interfering RNA) inhibition of the growth of luciferase-tagged PC3 (androgen-independent) prostate cancer in bone. 94 These interesting observations may provide potential methods for an imaging-based prediction and evaluation of metastatic prostate cancer.
Multifunctional nanometer probes based on semiconductor quantum dots may also offer a viable tool for molecular diagnostic imaging and therapy in prostate cancer. 95 In particular, multiplexed imaging of specific molecular targets with appropriate background noise reduction (eg, autofluoresence) and weak spectral signal amplification may be achieved in vivo. 96 The utility of such a platform for in vivo targeting of human prostate cancer in a nude mouse model has been demonstrated with both passive tumor targeting (permeation and retention) and active tumor targeting (through antibody binding to specific cell surface antigens).
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Summary
We briefly reviewed the underlying molecular and genetic alterations in prostate cancer and the current evidence on the emerging role of multimodality imaging in molecular profiling and characterization of this major public health problem. Molecular imaging will pave the way for direct translation of findings in animal models to the care of men with prostate cancer.
